Previous 10 | Next 10 |
Gainers: Clover Health Investments CLOV +21%. WM Technology MAPS +14%. bluebird bio (NASDAQ:BLUE) +7%. STAAR Surgical Company STAA +7%. MannKind Corporation MNKD +6%. Losers: Rent-A-Center RCII -31%. Pulmonx Corporation LUNG -20%. Five9 FIVN ...
Bluebird Bio is nearing approval of three potentially curative treatments for severe genetic diseases, although approval has been continually delayed. They recently left Europe over pricing disagreements, meaning they must convince US payors of the value of their expensive treatments,...
Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time. Let's address the second part of this stra...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I a...
FDA PDUFA goal dates for both therapies extended by three months bluebird bio, Inc . (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene...
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market Intelligence . Bluebird's shares hit the skids last Tuesday immediately after the company provi...
bluebird bio, Inc . (Nasdaq: BLUE) today announced planned updates to be presented at the 40 th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook. In 2022, bluebird is focused on the FDA review of two gene therapies –...
bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET. To access the live webcast of bluebird bio’s presentation, pl...
BioLife Solution is enjoying robust growth years over years. The company is riding the strong industry tailwinds as a logistics service provider for cell-based therapeutic innovators. Due to strategic acquisitions, BioLife is generating triple-digit top-line growth. For furt...
Shares of Bluebird Bio (NASDAQ: BLUE) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its clinical testing of lovo-cel in treating sickle cell disease on partial clinical hold. This p...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the ...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). S...